Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000207163 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cloning, Expression, Characterization and in silico studies of L-asparaginase from Vibrio sp. (GBPx3).
Biochimie
March 2025
Department of Medical Biotechnology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran; Non-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran. Electronic address:
L-asparaginase is a critical therapeutic enzyme for treating acute lymphoblastic leukemia (ALL), a common childhood malignancy. In this study, the L-asparaginase coding sequence from halophilic Vibrio sp. (GBPx3) was cloned, expressed in Escherichia coli, and characterized.
View Article and Find Full Text PDFAnti-Cancer Potential of a new Derivative of Caffeic Acid Phenethyl Ester targeting the Centrosome.
Redox Biol
March 2025
Department of Pathology, Medical University of Vienna, Vienna, Austria; European Research Initiative on ALK-Related Malignancies (ERIA), Cambridge, UK. Electronic address:
Anaplastic Large Cell Lymphoma (ALCL) is an aggressive T-cell lymphoma affecting children and young adults. About 30% of patients develop therapy resistance therefore new precision medicine drugs are highly warranted. Multiple rounds of structure-activity optimization of Caffeic Acid Phenethyl Ester have resulted in CM14.
View Article and Find Full Text PDFAdvances in Therapy of Adult Patients with Acute Lymphoblastic Leukemia.
Cells
March 2025
Department of Hematology and Medical Oncology, Advocate Lutheran General Hospital, Park Ridge, IL 60068, USA.
The landscape of adult acute lymphoblastic leukemia (ALL) is dramatically changing. With very promising results seen with novel immunotherapeutics in the setting of relapsed and refractory disease, the prospect of using these agents in first-line therapy has prompted the development of multiple clinical trials addressing this question. This review seeks to outline and expand the current standard of care, as well as new advances, in the treatment of adult patients with ALL and address future areas of research.
View Article and Find Full Text PDFExpression of CD47 protein in hematolymphoid neoplasms: Implications for CD47-mediated cancer immunotherapy.
Am J Clin Pathol
March 2025
Department of Pathology, Stanford University, Stanford, CA, United States.
Objectives: Recent studies show that blocking CD47-SIRPα interactions is a promising target in checkpoint inhibition for cancer immunotherapy. However, to date, the expression of CD47 is not well characterized in various hematolymphoid neoplasms.
Methods: This study evaluates CD47 expression in a wide range of hematolymphoid neoplasms using immunohistochemistry on 834 cases.
is a Major Prognostic Biomarker for Relapse in Childhood B-cell Acute Lymphoblastic Leukemia: A National Study of Unselected Cohort.
Balkan J Med Genet
December 2024
Center for Biomolecular Pharmaceutical Analyses, Faculty of Pharmacy, University Ss. Cyril and Methodius in Skopje, Mother Theresa 47, 1000 Skopje, N. Macedonia.
Although the identification of disease subtypes conveying prognostic significance along with minimal residual disease (MRD) assessment represent cornerstones for stratification in childhood acute lymphoblastic leukemia (ALL), approximately half of the relapses occur in patients from standard-risk groups. Identification of the drivers of treatment failure is crucial for detection of high-risk clones at diagnosis. We evaluated clinical variables and the most common genetic alterations in an unselected cohort of 55 patients with B-ALL treated according to the ALL-IC-BFM 2002 protocol, with a median follow-up of 46 months.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!